Stocks · News reference
Septerna (NASDAQ:SEPN) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.43) by 32.56 percent. This is a 48.21 percent increase over losses of $(0.56) per share from the
Reference Details
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
Keep reading
Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company focused on GPCR drug discovery, announced participation in two investor conferences in September 2026. The company also appointed industry veteran Rajiv Patni, M.D., as Chief Medical Officer. Septerna is advancing its Phase 1 clinical trial for SEP-479, an oral small molecule PTH1R agonist, with SAD/MAD data expected in Q1 2027.
Filed: 2026-08-25 AccNo: 0001193125-26-364210 Size: 154 KB Item 7.01: Regulation FD Disclosure Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
Jones Trading analyst Catherine Novack maintains Septerna (NASDAQ:SEPN) with a Buy and raises the price target from $43 to $62.